Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel for R/R LBCL
NCT06149169Phase 2Active, not recruiting
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Ming Ju Biotechnology. Started Aug 2023; status: active, not recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06149169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149169.